{"paper_id":"cbef6e09-245b-401b-accf-744b5517b362","body_text":"Abstract\nPrecancers are lesions that precede the development of invasive cancers. Nowadays, based on clinical, histopathological, and genetic evidence that will be reviewed herein, endometriosis is identified as the most likely precursor lesion for endometrioid or clear cell ovarian lesions. A strong epidemiological link with endometriosis has been reported in up to 40 % of endometrioid cancers and 50–90 % ovarian clear cell carcinoma; an association with adenofibromatous lesions is also known for both cancers. In this chapter, the author will attempt a comprehensive review of the precancerous lesions of ovarian clear cell and endometrioid carcinomas and review new advances including an attempt to explain most ovarian cancers with an origin outside the ovary, in particular the fallopian tube.\nIf a man will begin with certainties, he shall end in doubts; but if he will be content to begin with doubts he shall end in certainties.\nSir Francis Bacon. The Advancement of Learning (1605)\nAccess this chapter\nTax calculation will be finalised at checkout\nPurchases are for personal use only\nSimilar content being viewed by others\nReferences\nBerman JJ, Albores-Saavedra J, Bostwick D, Delellis R, Eble J, Hamilton SR, Hruban RH, Mutter GL, Page D, Rohan T, Travis W, Henson DE. Precancer: a conceptual working definition – results of a Consensus Conference. Cancer Detect Prev. 2006;30:387–94.\nGounaris I, Charnock-Jones SD, Brenton JD. Ovarian clear cell carcinoma—bad endometriosis or bad endometrium? J Pathol. 2011;225:157–60.\nVeras E, Mao TL, Ayhan A, et al. Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behaviour: a clinicopathologic analysis of 122 cases. Am J Surg Pathol. 2009;33:844–53.\nKurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm. Hum Pathol. 2011;42:918–31.\nKurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34:433–43.\nPearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, Chang-Claude J, Hein R, Lurie G, Wilkens LR, Carney ME, Goodman MT, Moysich K, Kjaer SK, Hogdall E, Jensen A, Goode EL, Fridley BL, Larson MC, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Vitonis AF, Titus LJ, Ziogas A, Brewster W, Anton-Culver H, Gentry-Maharaj A, Ramus SJ, Anderson AR, Brueggmann D, Fasching PA, Gayther SA, Huntsman DG, Menon U, Ness RB, Pike MC, Risch H, Wu AH, Berchuck A, Ovarian Cancer Association Consortium. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 2012;13:385–94.\nClement PB. History of gynecological pathology. IX. Dr. John Albertson Sampson. Int J Gynecol Pathol. 2001;20:86–101.\nClement PB. Pathology of endometriosis. Pathol Annu. 1990;25:245–95.\nClement PB. Diseases of the peritoneum. In: Kurman RJ, editor. Blaustein’s pathology of the female genital tract. 5th ed. New York, NY: Springer; 2002. p. 729–89.\nMeigs JV. Endometriosis-its significance. Ann Surg. 1941;114:866–74.\nSampson JA. Peritoneal endometriosis due to menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol. 1927;14:422–69.\nMeyer R. The current question of adenomyositis and adenomyomas in general and particularly seroepithelial adenomyositis and sarcomatoid adenomyometritis. Zentralbl Gynakol. 1919;43:745–50.\nMacleod D. Endometriosis; a surgical problem. Br J Surg. 1946;34:109–16.\nSampson JA. Metastatic or embolic endometriosis, due to the menstrual dissemination of endometrial tissue into the venous circulation. Am J Pathol. 1927;3:93–110.43.\nMeigs JV. Endometriosis. Ann Surg. 1948;127:795–808.\nLauchlan SC. The secondary Müllerian system revisited. Int J Gynecol Pathol. 1994;13:73–9.\nZheng W, Li N, Wang J, Ulukus EC, Ulukus M, Arici A, Liang SX. Initial endometriosis showing direct morphologic evidence of metaplasia in the pathogenesis of ovarian endometriosis. Int J Gynecol Pathol. 2005;24:164–72.\nBulun SE. Endometriosis. N Engl J Med. 2009;360:268–79.\nLucidi RS, Witz CA, Chrisco M, Binkley PA, Shain SA, Schenken RS. A novel in vitro model of the early endometriotic lesion demonstrates that attachment of endometrial cells to mesothelial cells is dependent on the source of endometrial cells. Fertil Steril. 2005;84:16–21.\nTseng JF, Ryan IP, Milam TD, et al. Interleukin-6 secretion in vitro is up-regulated in ectopic and eutopic endometrial stromal cells from women with endometriosis. J Clin Endocrinol Metab. 1996;81:1118–22.\nHornung D, Ryan IP, Chao VA, Vigne JL, Schriock ED, Taylor RN. Immunolocalization and regulation of the chemokine RANTES in human endometrial and endometriosis tissues and cells. J Clin Endocrinol Metab. 1997;82:1621–8.\nWu Y, Kajdacsy-Balla A, Strawn E, et al. Transcriptional characterizations of differences between eutopic and ectopic endometrium. Endocrinology. 2006;147:232–46.\nKao LC, Germeyer A, Tulac S, et al. Expression profiling of endometrium from women with endometriosis reveals candidate genes for disease-based implantation failure and infertility. Endocrinology. 2003;144:2870–81.\nOsteen KG, Bruner KL, Sharpe-Timms KL. Steroid and growth factor regulation of matrix metalloproteinase expression and endometriosis. Semin Reprod Endocrinol. 1996;14:247–55.\nDmowski WP, Gebel HM, Rawlins RG. Immunologic aspects of endometriosis. Obstet Gynecol Clin North Am. 1989;16:93–103.\nOsteen KG, Sierra-Rivera E. Does disruption of immune and endocrine systems by environmental toxins contribute to development of endometriosis? Semin Reprod Endocrinol. 1997;15:301–8.\nSeidman JD. Prognostic importance of hyperplasia and atypia in endometriosis. Int J Gynecol Pathol. 1996;15:1–9.\nFukunaga M, Nomura K, Ishikawa E, Ushigome S. Ovarian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology. 1997;30:249–55.\nCzernobilsky B, Morris WJ. A histologic study of ovarian endometriosis with emphasis on hyperplastic and atypical changes. Obstet Gynecol. 1979;53:318–23.\nLaGrenade A, Silverberg SG. Ovarian tumors associated with atypical endometriosis. Hum Pathol. 1988;19:1080–4.\nBallouk F, Ross JS, Wolf BC. Ovarian endometriotic cysts. An analysis of cytologic atypia and DNA ploidy patterns. Am J Clin Pathol. 1994;102:415–9.\nPrefumo F, Todeschini F, Fulcheri E, Venturini PL. Epithelial abnormalities in cystic ovarian endometriosis. Gynecol Oncol. 2002;84:280–4.\nSeidman JD. Ovarian atypical endometriosis. Histopathology. 1998;32:182.\nSainz de la Cuesta R, Eichhorn JH, Rice LW, et al. Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol. 1996;60:238–44.\nSchuger L, Simon A, Okon E. Cytomegaly in benign ovarian cysts. Arch Pathol Lab Med. 1986;110:928–9.\nOgawa S, Kaku T, Amada S, et al. Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study. Gynecol Oncol. 2000;77:298–304.\nNishida M, Watanabe K, Sato N, et al. Malignant transformation of ovarian endometriosis. Gynecol Obstet Invest. 2000;50 Suppl 1:18–25.\nMoll UM, Chumas JC, Chalas E, et al. Ovarian carcinoma arising in atypical endometriosis. Obstet Gynecol. 1990;75:537–9.\nOral E, Ilvan S, Tustas E, et al. Prevalence of endometriosis in malignant epithelial ovary tumours. Eur J Obstet Gynecol Reprod Biol. 2003;109:97–101.\nToki T, Fujii S, Silverberg SG. A clinicopathologic study of the association of endometriosis and carcinoma of the ovary using a scoring system. Int J Gynecol Cancer. 1996;6:68–75.\nAli-Fehmi R, Khalifeh I, Bandyopadhyay S, et al. Patterns of loss of heterozygosity at 10q23.3 and microsatellite instability in endometriosis, atypical endometriosis, and ovarian carcinoma arising in association with endometriosis. Int J Gynecol Pathol. 2006;25:223–9.\nSainz de la Cuesta R, Izquierdo M, Canamero M, et al. Increased prevalence of p53 overexpression from typical endometriosis to atypical endometriosis and ovarian cancer associated with endometriosis. Eur J Obstet Gynecol Reprod Biol. 2004;15:87–93.\nChalas E, Chumas J, Barbieri R, et al. Nucleolar organizing regions in endometriosis, atypical endometriosis, and clear cell and endometrioid carcinomas. Gynecol Oncol. 1991;40:260–3.\nFukunaga M, Ushigome S. Epithelial metaplastic changes in ovarian endometriosis. Mod Pathol. 1998;11:784–8.\nClement PB. The pathology of endometriosis: a survey of the many faces of a common disease emphasizing diagnostic pitfalls and unusual and newly appreciated aspects. Adv Anat Pathol. 2007;14:241–60.\nTanase Y, Furukawa N, Kobayashi H, Matsumoto T. Malignant transformation from endometriosis to atypical endometriosis and finally to endometrioid adenocarcinoma within 10 years. Case Rep Oncol. 2013;6:480–4.\nSakaki M, Hirokawa M, Sano T, Takahashi H, Tezuka K, Abe K, Sano M. Ovarian endometriosis showing decidual change and Arias-Stella reaction with biotin-containing intranuclear inclusions. Acta Cytol. 2003;47:321–4.\nVang R, Barner R, Wheeler DT, Strauss BL. Immunohistochemical staining for Ki-67 and p53 helps distinguish endometrial Arias-Stella reaction from high-grade carcinoma, including clear cell carcinoma. Int J Gynecol Pathol. 2004;23:223–33.\nNoble LS, Simpson ER, Johns A, Bulun SE. Aromatase expression in endometriosis. J Clin Endocrinol Metab. 1996;81:174–9.\nNoble LS, Takayama K, Zeitoun KM, et al. Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. J Clin Endocrinol Metab. 1997;82:600–6.\nBurney RO, Talbi S, Hamilton AE, et al. Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. Endocrinology. 2007;148:3814–26.\nSharpe-Timms KL, Cox KE. Paracrine regulation of matrix metalloproteinase expression in endometriosis. Ann N Y Acad Sci. 2002;955:147–56.\nUlukus M, Ulukus EC, Seval Y, Zheng W, Arici A. Expression of interleukin-8 receptors in endometriosis. Hum Reprod. 2005;20:794–801.\nAkoum A, Jolicoeur C, Boucher A. Estradiol amplifies interleukin-1-induced monocyte chemotactic protein-1 expression by ectopic endometrial cells of women with endometriosis. J Clin Endocrinol Metab. 2000;85:896–904.\nXue Q, Lin Z, Cheng YH, et al. Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis. Biol Reprod. 2007;77:681–7.\nKobayashi H, Kajiwara H, Kanayama S, Yamada Y, Furukawa N, Noguchi T, Haruta S, Yoshida S, Sakata M, Sado T, Oi H. Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary. Oncol Rep. 2009;22:233–40.\nJiang X, Hitchcock A, Bryan EJ, Watson RH, Englefield P, Thomas EJ, Campbell IG. Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci. Cancer Res. 1996;56:3534–9.\nSato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cysts of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res. 2000;60:7052–6.\nPrefumo F, Venturini PL, Fulcheri E. Analysis of p53 and c-erb-2 expression in ovarian endometrioid carcinomas arising in endometriosis. Int J Gynecol Pathol. 2002;22:83–8.\nKolasa IK, Rembiszewska A, Janiec-Jankowska A, Dansonka-Mieszkowska A, Lewandowska AM, Konopka B, Kupryjanczyk J. Pten mutation, expression and loh at its locus in ovarian carcinomas. Relation to tp53, k-ras and brca1 mutations. Gynecol Oncol. 2006;103:692–7.\nPalacios J, Gamallo C. Mutations in the beta-catenin gene (ctnnb1) in endometrioid ovarian carcinomas. Cancer Res. 1998;58:1344–7.\nWorley MJ, Welch WR, Berkowitz RS, Ng SW. Endometriosis-associated ovarian cancer: a review of pathogenesis. Int J Mol Sci. 2013;14:5367–79.\nWillner J, Wurz K, Allison KH, Galic V, Garcia RL, Goff BA, Swisher EM. Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum Pathol. 2007;38:607–13.\nKuo KT, Mao TL, Jones S, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 2009;174:1597–601.\nYamamoto S, Tsuda H, Takano M, et al. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinomas. J Pathol. 2011;225:189–94.\nYamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. Virchows Arch. 2012;460:77–87.\nTsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, Ohki M, Yasugi T, Taketani Y, Hirohashi S. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol. 2003;163:2503–12.\nFadare O, Liang SX. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma. Appl Immunohistochem Mol Morphol. 2012;20:580–7.\nKato N, Sasou S, Motoyama T. Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol. 2006;19:83–9.\nWiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363:1532–43.\nYamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with pik3ca mutations. Mod Pathol. 2012;25:615–24.\nSchiller W. Parvilocular tumors of the ovary. Arch Pathol. 1943;35:391–413.\nSchiller W, Rilke F, Degna AT. Parvilocular cystomas of the ovary: report of two cases. Obstet Gynecol. 1957;10:28–33.\nAnderson MC, Langley FA. Mesonephroid tumours of the ovary. J Clin Pathol. 1970;23:210–8.\nScully RE, Barlow JF. “Mesonephroma” of ovary: tumor of Mullerian nature related to the endometrioid carcinoma. Cancer (Phila). 1967;20:1405–17.\nScully RE, Young RH, Clement PB. Endometrioid tumors. In: Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Washington, DC: Armed Forces Institute of Pathology; 1998. p. 107–50.\nBell DA, Scully RE. Benign and borderline clear cell adenofibromas of the ovary. Cancer. 1985;56:2922–31.\nKennedy AW, Biscotti CV, Hart WR, et al. Ovarian clear cell adenocarcinoma. Gynecol Oncol. 1989;32:342–9.\nRoth LM, Langley FA, Fox H, et al. Ovarian clear cell adenofibromatous tumors. Benign, of low malignant potential, and associated with invasive clear cell carcinoma. Cancer. 1984;53:1156–63.\nYamamoto S, Tsuda H, Takano M, Hase K, Tamai S, Matsubara O. Clear-cell adenofibroma can be a clonal precursor for clear-cell adenocarcinoma of the ovary: a possible alternative ovarian clear-cell carcinogenic pathway. J Pathol. 2008;216:103–10.\nYamamoto S, Tsuda H, Suzuki K, et al. An allelotype analysis indicating the presence of two distinct ovarian clear-cell carcinogenic pathways: endometriosis-associated pathway vs. clear-cell adenofibroma-associated pathway. Virchows Arch. 2009;455:261–70.\nZhao C, Wu LS, Barner R. Pathogenesis of ovarian clear cell adenofibroma, atypical proliferative (borderline) tumor, and carcinoma: clinicopathologic features of tumors with endometriosis or adenofibromatous components support two related pathways of tumor development. J Cancer. 2011;2:94–106.\nKao GF, Norris HJ. Unusual cystadenofibromas: endometrioid, mucinous, and clear cell types. Obstet Gynecol. 1979;54:729–36.\nRoth LM, Czernobilsky B, Langley FA. Ovarian endometrioid adenofibromatous and cystadenofibromatous tumors: benign, proliferating, and malignant. Cancer. 1981;48:1838–45.\nBell KA, Kurman RJ. A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary. Am J Surg Pathol. 2000;24:1465–79.\nSampson JA. Endometrial carcinoma of ovary, arising in endometrial tissue in that organ. Arch Surg. 1925;10:1–72.\nScully RE, Richardson GS, Barlow JF. The development of malignancy in endometriosis. Clin Obstet Gynecol. 1966;9:384–411.\nHughesdon PE. Adenofibroma of ovary with partial differentiation to endometriosis. Proc Roy Soc Med. 1949;42:62–3.\nSerov SF, Scully RE, Sobin LH. International histologic classification and staging of tumors, no. 9. In: Histologic typing of ovarian tumors. Geneva: World Health Organization; 1973.\nBell DA, Scully RE. Atypical and borderline endometrioid adenofibromas of the ovary. A report of 27 cases. Am J Surg Pathol. 1985;9:205–14.\nPiura B, Goldstein J, Yanai I. Ovarian endometrioid carcinoma with an adenofibromatous pattern. Int J Tissue React. 1986;8:249–54.\nGaing AA, Kimble CC, Belmonte AH, Agustin E, Tchertkoff V. Invasive ovarian endometrioid adenofibroma with omental implants and collision with endometrial adenocarcinoma. Obstet Gynecol. 1988;7:440–4.\nSnyder RR, Norris HJ, Tavassoli F. Endometrioid proliferative and low malignant potential tumors of the ovary. A clinicopathologic study of 46 cases. Am J Surg Pathol. 1988;12:661–71.\nCrum CP, Herfs M, Ning G, Bijron JG, Howitt BE, Jimenez CA, Hanamornroongruang S, McKeon FD, Xian W. Through the glass darkly: intraepithelial neoplasia, top-down differentiation, and the road to ovarian cancer. J Pathol. 2013;231:402–12.\nPiek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195:451–6.\nDubeau L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol Oncol. 1999;72:437–42.\nYuan Z, Wang L, Wang Y, Zhang T, Li L, Cragun JM, Chambers SK, Kong B, Zheng W. Tubal origin of ovarian endometriosis. Mod Pathol. 2014;27:1154–62.\nvan der Horst PH, van der Zee M, Heijmans-Antonissen C, Jia Y, DeMayo FJ, Lydon JP, van Deurzen CH, Ewing PC, Burger CW, Blok LJ. A mouse model for endometrioid ovarian cancer arising from the distal oviduct. Int J Cancer. 2014;135:1028–37.\nTanwar PS, Kaneko-Tarui T, Lee HJ, Zhang L, Teixeira JM. PTEN loss and HOXA10 expression are associated with ovarian endometrioid adenocarcinoma differentiation and progression. Carcinogenesis. 2013;34:893–901.\nLi J, Fadare O, Xiang L, et al. Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis. J Hematol Oncol. 2012;5:8.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nEditor information\nEditors and Affiliations\nRights and permissions\nCopyright information\n© 2016 Springer International Publishing Switzerland\nAbout this chapter\nCite this chapter\nRoma, A.A. (2016). Precancerous Lesions of Ovarian Clear Cell and Endometrioid Carcinomas. In: Fadare, O. (eds) Precancerous Lesions of the Gynecologic Tract. Springer, Cham. https://doi.org/10.1007/978-3-319-22509-8_3\nDownload citation\nDOI: https://doi.org/10.1007/978-3-319-22509-8_3\nPublisher Name: Springer, Cham\nPrint ISBN: 978-3-319-22508-1\nOnline ISBN: 978-3-319-22509-8\neBook Packages: MedicineMedicine (R0)","source_license":"CC0","license_restricted":false}